Back to Health A to Z. Herceptin is the brand name of a medicine called trastuzumab. Herceptin can help control the growth of cancer cells that contain high amounts of HER2 human epidermal growth factor receptor 2.
The finding comes from the third analysis of the Herceptin Adjuvant HERA triala large multicenter study that compared outcomes in patients randomly assigned to receive standard chemotherapy followed by trastuzumab with those in patients randomly assigned to receive chemotherapy alone the observation group. The 4-year follow-up results were reported February 25,in Lancet Oncology. Luca Gianni, M.
By Caroline Helwick February 10, Advertisement. Joensuu said. Chemotherapy plus 1 year of anti-HER2 therapy should remain the standard.
Herceptin is approved, in combination with chemotherapy cisplatin and either capecitabine or 5-fluorouracilfor the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction where the esophagus meets the stomach in patients who have not received prior treatment for their metastatic disease. Be sure to contact your doctor if you are experiencing any of the following:. These include heart problems—such as congestive heart failure or reduced heart function—with or without symptoms.
Researchers say six months of Herceptin treatment for early stage breast cancer may be as effective as taking the drug for an entire year. Herceptin, the brand name for trastuzumab, is used to treat all stages of HER2-positive breast cancer. But this trial focused on early stage disease.
What is trastuzumab? How does trastuzumab work? Who might be offered trastuzumab?
Hormone receptor HR status and the expression of human epidermal growth factor receptor 2 HER2 are two of the most important factors used for the categorization of breast cancer Goldhirsch et al. They are prognosticators for survival and are predictive for response to endocrine and anti-HER2 therapy, respectively Goldhirsch et al. Initially, the role of HR status in trastuzumab efficacy was based on data from the neoadjuvant therapy of HER2-positive breast cancer.
Trastuzumab is given by slow intravenous I. A healthcare professional gives the infusion once a week or once every 3 weeks. The first dose of trastuzumab is higher. It will usually take about 90 minutes and can be slowed or stopped if the woman feels uncomfortable.
These targeted drugs are designed to block the growth and spread of cancer cells. These drugs work differently from chemotherapy drugs, which attack all cells that are growing quickly including cancer cells. Targeted drugs sometimes work even when chemo drugs do not.